The anti-proliferation activity of extracted MGDG was compared against the MGDG standard in HER2-positive BT-474 (Fig. 7a) and MDA-MB-231 triple-negative breast cancer cells (Fig. 7b). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.